Tag Archives: PARTNER 3

El aumento de la experiencia de los operadores mejora los resultados en el TAVI

TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.

TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.

At two-year followup, primary end point continued to be significantly lower with Sapien 3 vs. conventional surgery, but the initial difference in death and stroke in favor of TAVR started to shrink.  In addition, there was higher risk of valve thrombosis in TAVR patients.  The PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter

ACC 2020 Virtual | PARTNER 3: TAVI vs cirugía en bajo riesgo a 2 años de seguimiento

Virtual ACC 2020 | PARTNER 3: TAVR vs CABG in Low Risk at 2 Years

The 2-year outcomes in patients with severe aortic stenosis and low surgical risk continue to show a numerical benefit in favor of transcatheter aortic valve replacement (TAVR) vs. surgical replacement (CABG) for the primary end point of death, stroke or repeat hospitalization for cardiovascular reasons. However, the initially higher advantage of TAVR has been narrowing

Highlights TCT 2019

TCT 2019 | PARTNER 3: Obvious Short-Term Quality of Life Improvement, but What Happens Afterwards?

Courtesy of SBHCI. Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation. This work, presented at the TCT 2019 Scientific Sessions

Highlights TCT 2019

TCT 2019 | PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

Courtesy of the SBHCI. Discover the results of the PARTNER 3 study, presented during TCT Congress 2019.   Link to the SBHCI publication HERE Original Title: PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves. Author of the original title: Raj Makkar. We are interested in your opinion. Please,

ACC 2019 | PARTNER 3: TAVI en bajo riesgo con menos eventos al año que la cirugía

ACC 2019 | PARTNER 3: Low Risk TAVR vs. Surgery, Fewer Events per Year

Courtesy of Dr. Carlos Fava. TAVR has largely been shown superior or non-inferior in high or intermediate risk patients.  Indeed, the development of new technologies, the more simplified procedure and the increased experience of operators and team have allowed these groups to benefit from this strategy. However, there is little evidence available on low risk

Top